Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Ferring Pharmaceuticals	55566100001	ganirelix	2019-02-14	184.0200	None	1	None	1	None	2018-12-14	None	1	None	1) report previously submitted so we do not agree we are delinquent 2)number of patients is non public	None
Fresenius Kabi USA LLC	63323082320	Ertapenem for Injection, 1g Vial. (10 vials per pack)	2019-12-09	1286.6000	None	1	None	None	None	2019-09-16	None	1	The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	The information contained in this report is subject to the following limitations and assumptions. (1)	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2)
Fresenius Kabi USA LLC	65219016010	Busulfan Injection 60mg 10mL Vial (8 vials per pack)	2019-12-04	2500.0000	None	1	None	None	None	2019-05-21	None	1	The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	The information contained in this report is subject to the following limitations and assumptions. (1)	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2)